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Abstract 
BACKGROUND: The C-159T polymorphism of the CD14 receptor gene can be associated with the development 
of atopic dermatitis. Probiotics can modulate chronic inflammation through activation of the CD14 receptor. So, 
the efficacy of probiotic therapy can be dependent on this genetic polymorphism.  
AIM: The purpose of the study was to investigate the efficacy of adding probiotic (Lactobacillus acidophilus, LA-5 
and Bifidobacterium animalis subsp. lactis, ВВ-12) to standard treatment (ointment of fluticasone propionate 
0.005% and emollient) of atopic dermatitis in adults during 28 days, depending on the stratification of patients on 
CC or TT genotypes of the CD14 receptor gene. 
MATERIAL AND METHODS: The study included 37 adult patients with AD. There were identified 19 patients with 
exogenous (IgE-dependent) and 18 with endogenous (IgE-dependent) AD. To evaluate the efficacy of the 
probiotics all patients were divided into three groups for both exogenous and endogenous AD. The first group was 
selected from patients with CC genotype (C-159T) who received standard therapy (ointment of fluticasone 
propionate 0.005% – 2 times a day, emollients – 2 times a day) and probiotic (Lactobacillus acidophilus, LA-5 and 
Bifidobacterium animalis subsp. lactis, ВВ-12 - 1 capsule 2 times per day) The second group included patients 
with CC genotype, who received only standard therapy. The third group was presented by patients with TT 
genotype (C-159T) who received standard therapy and probiotic. The SCORAD and DLQI parameters were 
evaluated on Day 0, 14 and 28. The level of IL-4, IL-5, IL-10, TGF-β cytokines was determined on Day 0 and Day 
28.  
RESULTS: The results of our study found that the addition of probiotics (Lactobacillus acidophilus, LA-5 and 
Bifidobacterium animalis subsp. lactis, ВВ-12) to standard treatment (ointment of fluticasone propionate 0.005%, 
emollient) significantly increased the effectiveness of treatment of atopic dermatitis in adults with exogenous form 
and CC genotype (C-159T), confirmed by clinical (a significant decrease of SCORAD and DLQI indices) and 
immunological criteria (a significant decrease of IL-4 and an increase of TGF-β). 
CONCLUSION: Simultaneous determination of the exogenous or endogenous form, identification of the C-159T 
genotypes, evaluation of the serum level of IL-4 and TGF-β can serve as an algorithm for the personalised 
treatment of patients with atopic dermatitis. 
 
 
 
Introduction 
 
To date, there are practically no drugs for the 
treatment of atopic dermatitis (AD) that can modify 
chronic inflammation or activate natural suppressor 
immune mechanisms, especially by activating 
regulatory T-lymphocytes. However, probiotics 
themselves may have such properties. 
Probiotics are living microorganisms that can 
be of benefit to health when administered in adequate 
doses [1]. The most commonly used are 
Lactobacillus, Bifidobacterium, Enterococcus, 
Propionibacterium and some yeasts such as 
Saccharomyces boulardii. Their benefit is proven in 
the treatment of diarrhoea after taking antibiotics, 
irritable bowel syndrome and inflammatory bowel 
disease [2]. Genetic polymorphism and the effect of 
microorganisms on the immune system are closely 
related to the modulation of skin inflammation in AD, 
including the activation of the CD14/TLR-4 receptor 
complex by endotoxin of gram-negative bacteria.  
The CD14 receptor gene is located on 
chromosome 5q31.1, has two exons and 3900 
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nucleotides [3]. In the same locus, there are genes 
responsible for the synthesis of IgE. There are many 
studies of the C-159T polymorphism (rs2569190) of 
the CD14 receptor gene in atopic patients [4]. For this 
polymorphism, cytosine (C) is replaced by thymine (T) 
at position 159 of the promoter region, resulting in the 
population presence of homozygotes of cytosine and 
thymine (CC, TT) and heterozygotes cytosine-thymine 
(CT) [3] 
This polymorphism can affect the 
development of various diseases in different ways. 
The risk of nasal allergies and atopy was the most 
reduced in the subjects who combined both an early-
life exposure to a farming environment and the -
159TT genotype [5]. Although сhildren with C/C 
variant of CD14 C-159T had a significantly lower 
prevalence of croup [6]. 
It has been shown that the number of positive 
skin tests was significantly higher in patients with CC 
genotype compared with TT [3]. In the Netherlands, it 
was found that in patients with positive skin tests, the 
level of total IgE was significantly (p < 0.05) higher in 
CC compared to TT genotype [7]. In Australia, it was 
found that the risk of atopy in children is significantly 
higher in CC genotype (OR = 2.0, P = 0.04) [8]. In 
China, one study has shown that atopic subjects with 
CC genotype had the highest serum total IgE levels 
compared with CT and TT genotypes [9]. Another 
research has shown that TT homozygotes are more 
common in adult patients with allergic rhinitis among 
the Chinese population and the C-159T polymorphism 
was not associated with serum IgE levels [10]. Other 
studies indicate that C-159T gene polymorphism can 
be associated with elevated levels of soluble CD14 
[11], [12]. 
In turn, probiotics have antagonistic properties 
regarding activation mechanisms of inflammation, 
including endotoxin-dependent ones. So, probiotics 
stimulate regulatory T-lymphocytes, increase the 
synthesis of IF-β and TGF-β, inhibit the function of T-
helper type 2, reduce the secretion of TNF-α and 
eosinophilic cationic protein, reduce the concentration 
of total and specific IgE, reduce colonisation of the 
skin by Staphylococcus aureus and restore its barrier 
function [13]. 
Identifying phenotypes and genotypes, on the 
one hand, and potential biomarkers on the other, are 
vital elements for the successful development of new 
and personalised therapeutic approaches in patients 
with AD [14]. 
The purpose of the study was to investigate 
the efficacy of adding probiotic (Lactobacillus 
acidophilus, LA-5 and Bifidobacterium animalis subsp. 
lactis, ВВ-12) to standard treatment (ointment of 
fluticasone propionate 0.005% and emollient) of atopic 
dermatitis in adults during 28 days, depending on the 
stratification of patients on CC or TT genotypes of the 
CD14 receptor gene. 
Material and Methods 
 
The study included 37 adult patients with AD. 
For the diagnosis of atopic dermatitis, we used the 
recommendations provided by the European 
Academy of Dermatology and Venereology [15].  
All patients with atopic dermatitis, depending 
on the level of total IgE and at least one allergen's 
positivity by skin prick tests, were divided into two 
main groups: exogenous or IgE-dependent AD (total 
IgE level greater than 100 IU/ml) and endogenous 
IgE-independent AD (total IgE level less than 100 
IU/ml). The level of total IgE was determined by 
ELISA method. 
There were identified 19 patients with 
exogenous (IgE-dependent) and 18 with endogenous 
(IgE-dependent) AD. 
Allele-specific PCR with electrophoretic 
detection was used to access gene polymorphisms of 
the CD14 receptor (C-159T, rs2569190). Allele-
specific PCR was performed using kit: "Mutation of 
monocyte differentiation antigen (CD14) C-159T" 
(Lytech, Russia) according to the manufacturer's 
instructions. 
The level of IL-4, IL-5, IL-10, TGF-β in serum 
was determined by ELISA method. 
Determination of the severity of the disease 
was carried out using SCORAD (SCORing Atopic 
Dermatitis) index [16]. The quality of life of the 
patients was assessed using the DLQI questionnaire 
(Dermatitis Quality of Life Index) [17].  
The clinical trial was conducted as open, 
controlled, randomised, in 6 parallel groups during 28 
days at the departments of dermatology and clinical, 
laboratory immunology and Allergology of the Shupyk 
National Medical Academy of Postgraduate 
Education. 
To study the efficacy of the probiotics 
(Lactobacillus acidophilus, LA-5 and Bifidobacterium 
animalis subsp. lactis, ВВ-12) on the severity of the 
disease, quality of life and immune parameters, 
genotypes of CC and TT, all patients were divided into 
three groups for both exogenous and endogenous 
AD. The first groups were selected from patients with 
CC genotype (C-159T) who received standard therapy 
(ointment of fluticasone propionate 0.005% – 2 times 
a day, emollients – 2 times a day) and probiotic 
(Lactobacillus acidophilus, LA-5 and Bifidobacterium 
animalis subsp. lactis, ВВ-12 - 1 capsule 2 times per 
day) The second group included patients with CC 
genotype, who received only standard therapy. The 
third group was presented by patients with TT 
genotype (C-159T) who received standard therapy 
and probiotic. The SCORAD and DLQI parameters 
were evaluated on Day 0, 14 and Day 28. The level of 
IL-4, IL-5, IL-10, TGF-β cytokines was determined on 
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Day 0 and Day 28. 
All results were analysed using "Minitab 16" 
statistical software. In the analyses, the normality test 
was done using the Kolmogorov-Smirnov test. The 
comparison of central tendencies of two independent 
samples was performed using the U-Mann-Whitney 
test. Comparison of the average of two independent 
samples used Student's criterion for non-normally and 
normally distributed samples, respectively. 
Quantitative variables are presented as mean values 
and standard deviation (SD) or 95% confidence 
intervals for normally distributed data, and the median 
with first (Q1) and third (Q3) quartile or 95% 
confidence intervals for non-normally distributed data. 
For multiple comparisons, the Kruskal-Wallis test and 
ANOVA (Bonferroni and Sheffe correction) were used.  
All study subjects provided written informed 
consent to participate in this research. Ethics approval 
was received from the Bioethics Committee of the 
Shupyk National Medical Academy of Postgraduate 
Education, Kyiv, Ukraine.  
 
 
Results 
 
The average age of patients with exogenous 
AD (28.32 ± 11.70 years) did not significantly differ (p 
= 0.520) from endogenous (29.11 ± 9.99 years) one. 
Groups did not differ significantly (P = 0.851) by 
gender (exogenous AD, male to male ratio 11/8; 
endogenous AD, female/male ratio – 10/8). The 
duration of the disease (exogenous AD – 17.68 ± 6.39 
years, endogenous AD – 16.44 ± 7.04, p = 0.676) and 
the number of exacerbations in the last year 
(exogenous AD – 3.00 ± 0.94, endogenous AD – 2.78 
± 1.06, p = 0.625) also did not significantly differ. 
The assessment of the SCORAD index on 
Day 0, 14 and 28 are provided in Table 1. 
Table 1: The dynamics of SCORAD scores in patients that 
underwent the different treatments 
Groups Day 0 Day 14 Day 28 P1 
Exogenous AD CC genotype, 
standard therapy + 
probiotics, n = 7 
12.00 
(10.50-21.52) 
6.00 
(2.50-10.02)# 
3.00 
(2.00-5.51)# 
0.001 
СС genotype, 
standard therapy, n = 6 
12.50 
(8.19-18.61) 
7.50 
(6.19-16.61) 
5.50 
(4.19-14.81)* 
0.121 
TT genotype, 
standard therapy + 
probiotics, n = 6 
14.00 
(10.19-22.42) 
8.50 
(6.39-14.81) 
6.50 (4.19-
11.23)* # 
0.015 
 P2 0.786 0.132 0.022  
Endogenous AD CC genotype, 
standard therapy + 
probiotics, n = 6 
14.50 
(9.19-21.42) 
9.00 
(6.27-12.73)# 
6.00 
(4.19-7.81)# 
0.006 
CC genotype, 
standard therapy, n = 6 
14.00 
(11.19-20.61) 
11.00 
(8.39-16.03) 
9.50 
(7.19-13.42)*# 
0.039 
TT genotype, 
standard therapy + 
probiotics, n = 6 
16.00 
(10.00-23.42) 
11.00 
(7.39-13.61) 
8.50 
(6.19-9.81)*# 
0.011 
 P2 0.891 0.558 0.020  
Note: P1 – reliability in multiple comparison with the use of the Kruskal-Wallis test in the group on Day 0, 14 
and 28; P2 – reliability in multiple comparisons by using the Kruskal-Wallis test between groups; * – 
significance of differences between the group with the CC genotype (standard therapy + probiotics) from the 
groups with the CC genotype (standard therapy) and TT genotype (standard therapy + probiotics), p < 0.05; 
# – significance of differences between groups on Day 0 compared with 14 and 28, p < 0.05; Me – median, 
95% CI – 95% confidence interval of the median. 
 
There was estimated that standard treatment 
with probiotics during 28 days significantly reduced 
the SCORAD index in exogenous AD patients with CC 
and TT genotypes (Table 1). Patients with CC 
genotype who received standard therapy with 
probiotics had the most significant reduction of 
SCORAD index on Day 28.  
Table 2: The dynamics of DLQI scores in patients that 
underwent the different treatments 
Groups Day 0 Day 14 Day 28 P1 
Exogenous 
AD 
СС genotype, 
standard therapy + 
probiotics, n = 7 
10.00 (7.50-
15.53) 
7.00 (4.50-
10.01)# 
3.00 (2.00-
3.50)# 
0.001 
СС genotype, 
standard therapy, n = 
6 
9.50 (7.19-
19.06) 
6.50 (5.19-
15.25) 
4.50 (3.19-
12.45)*# 
0.037 
TT genotype, 
standard therapy + 
probiotics, n = 6 
12.50 (6.19-
21.42) 
9.50 (4.19-
14.81) 
6,00 (3.19-
11.61)* 
0.150 
 P2 0.841 0.715 0.012  
Endogenous 
AD 
СС genotype, 
standard therapy + 
probiotics, n = 6 
12.50 (6.39-
19.42) 
8,50 (5.00-
13.42) 
5,50 (3.19-
8.42)# 
0.034 
СС genotype, 
standard therapy, n = 
6 
11.00 (7.39-
17.42) 
7.00 (4.19-
11.81) 
4.50 (3.19-
8.81)# 
0.027 
TT genotype, 
standard therapy + 
probiotics, n = 6 
13.50 (8.19-
19.42) 
10.00 (6.19-
13.81 
6.00 (4.19-
9.81)# 
0.031 
 P2 0.816 0.442 0.544  
Note: same as in Table 1. 
 
There was a significant decrease in SCORAD 
index (Table 1) in patients of all groups who had 
endogenous AD. It was significantly lower (p = 0.020) 
in patients with the CC genotype who received 
standard treatment with probiotics compared to other 
groups.  
The next step was to analyse the quality of life 
of patients during treatment. The assessment of the 
DLQI index is provided in Table 1. 
Table 3: The serum level of IL-4 (pg/ml) in patients that 
underwent different treatments 
Groups Day 0 Day 28 P1 
Exogenous AD СС genotype, 
standard therapy + 
probiotics, n = 7 
41.70 
(19.98-43.81)* 
12.90 
(11.50-18.43) 
0.004 
СС genotype, 
standard therapy, n = 6 
30.20 
(24.34-42.51)* 
24.15 
(14.16-34.77)* 
0.240 
TT genotype, 
standard therapy + 
probiotics, n = 6 
9.80 
(8.12-24.58) 
9.85 
(6.73-19.47) 
0.699 
 P2 0.014 0.010  
Endogenous AD СС genotype, 
standard therapy + 
probiotics, n = 6 
29.05 
(18.87-42.11)* 
23.00 
(16.32-30.39)* 
0.240 
СС genotype, 
standard therapy, n = 6 
29.90 
(25.13-39.56)* 
24.20 
(18.07-34.08)* 
0.078 
TT genotype, 
standard therapy + 
probiotics, n = 6 
16.35 
(9.91-24.43) 
12.90 
(8.53-19.42) 
0.310 
 P2 0.017 0.023  
Note: P1 – comparison of central tendencies between 0 and day 28 using the Mann-
Whitney U-test; P2 – reliability in multiple comparisons using the Kruskal-Wallis test 
between groups; * – significance of differences between groups with TT genotype 
(standard therapy + probiotics) from groups with CC genotype (standard therapy) and CC 
genotype (standard therapy + probiotics), p <0.05; # – significance of differences between 
the group with CC genotype (standard therapy + probiotics) from the group with the 
genotype CC (standard therapy), P <0.05. 
 
For the exogenous form of AD (Table 2), 
there was a significant decrease in DLQI scores on 
Day 28 for patients in both treatment groups who had 
CC genotype. For patients with TT genotype, results 
did not reach the level of statistical significance (p = 
0.150). On the contrary, for endogenous AD there was 
a significant decrease in DLQI score for all groups. 
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The lowest score was observed in patients with CC 
genotype (standard treatment + probiotics), which 
significantly differed (p = 0.012) from other groups in 
the exogenous form of AD. 
Dynamics of the concentration of IL-4 is 
provided in Table 3. 
On Day 0, the serum level of IL-4 (Table 3) in 
patients with TT genotype was significantly lower 
compared to CC genotype in both groups for 
exogenous and endogenous AD. On Day 28 (Table 
3), there was a significant decreased (p = 0.004) of 
this cytokine only in patients with CC genotype and 
exogenous form of AD who received standard therapy 
with probiotics. For endogenous AD, no such 
significant changes have been observed. 
Table 4: The serum level of IL-5 (pg/ml) in patients that 
underwent different treatments 
Groups Day 0 Day 28 P1 
Exogenous AD СС genotype, 
standard therapy + 
probiotics, n = 7 
30.70 
(23.18-43.16)* 
23.10 
(16.74-35.14)* 
0.074 
СС genotype, 
standard therapy, n = 6 
28.80 
(20.68-44.06)* 
24.50 
(15.72-34.93)* 
0.132 
TT genotype, 
standard therapy + 
probiotics, n = 6 
20.50 
(10.64-25.46) 
13.85 
(9.62-21.56) 
0.240 
 P2 0.023 0.048  
Endogenous AD СС genotype, 
standard therapy + 
probiotics, n = 6 
28.10 
(20.59-45.97)* 
24.65 
(15.64-37.95)* 
0.394 
СС genotype, 
standard therapy, n = 6 
35.40 
(29.87-48.62)* 
29.85 
(24.59-39.20)* 
0.240 
TT genotype, 
standard therapy + 
probiotics, n = 6 
15.80 
(9.77-23.45) 
12.40 
(8.86-18.91) 
0.379 
 P2 0.003 0.004  
Note: same as in Table 3. 
 
In patients with TT genotype, the level of IL-5 
(Table 4) was significantly lower in comparison to 
other groups on Day 0 and on Day 28. During 
treatment, the concentration of IL-5 (Table 4) did not 
significantly change in any of the studied groups.  
Table 5: The serum level of IL-10 (pg/ml) in patients that 
underwent different treatments 
Groups Day 0 Day 28 P1 
Exogenous AD СС genotype, 
standard therapy + 
probiotics, n = 7 
15.40 
(10.15-26.45)* 
22.20 
(13.65-30.20)* 
0.210 
СС genotype, 
standard therapy, n = 6 
19.25 
(11.98-26.52)* 
18.90 
(14.69-32.67)* 
0.589 
TT genotype, 
standard therapy + 
probiotics, n = 6 
44.65 
(39.99-56.23) 
46.75 
(37.01-62.68) 
0.818 
 P2 0.003 0.003  
Endogenous AD СС genotype, 
standard therapy + 
probiotics, n = 6 
25.70 
(16.34-37.96)* 
27.70 
(19.87-38.24)* 
0.749 
СС genotype, 
standard therapy, n = 6 
23.55 
(16.68-43.63)* 
25.20 
(21.07-46.01)* 
0.589 
TT genotype, 
standard therapy + 
probiotics, n = 6 
58.45 
(37.61-70.55) 
67.85 
(47.97-75.34) 
0.485 
 P2 0.008 0.004  
Note: same as in Table 3. 
 
In turn, the concentration of IL-10 (Table 5) 
was significantly higher at the beginning and the end 
of treatment in the groups of patients with TT 
genotype compared to CC genotype. The treatment of 
exogenous and endogenous AD did not lead to 
significant changes in the level of IL-10. 
Table 6: The serum level of TGF-β (pg/ml) in patients that 
underwent different treatments 
Groups Day 0 Day 28 P1 
Exogenous AD СС genotype, 
standard therapy + 
probiotics, n = 7 
16.10 
(13.69-21.61)* 
35.90 
(28.64-47.48)# 
0.001 
СС genotype, 
standard therapy, n = 6 
17.40 
(12.91-25.43)* 
18.30 
(13.84-20.10)*# 
0.998 
TT genotype, 
standard therapy + 
probiotics, n = 6 
41.90 
(31.81-50.34) 
39.85 
(32.66-52.83) 
0.998 
 P2 0.003 0.002  
Endogenous AD СС genotype, 
standard therapy + 
probiotics, n = 6 
16.70 
(11.12-32.59)* 
18.20 
(12.84-29.77)* 
0.818 
СС genotype, 
standard therapy, n = 6 
17.75 
(13.17-26.64)* 
17.95 
(12.12-29.88)* 
0.810 
TT genotype, 
standard therapy + 
probiotic, n = 6 
46.90 
(34.86-50.23) 
46.85 
(37.12-53.04) 
0.631 
 P2 0.003 0.003  
Note: same as in Table 3. 
 
The dynamics of TGF-β in contrast to IL-10 
was different. Thus, in patients with CC genotype and 
exogenous form of AD (Table 6) who received 
standard treatment and probiotics, the level of TGF-β 
(p = 0.001) was significantly increased by Day 28 
compared to Day 0. Also, the level of TGF-β in this 
group on Day 28 did not significantly differ from the 
group with TT genotype. In all other cases, the 
concentration of this cytokine in TT genotype (Table 
6) was significantly higher compared to CC genotype. 
 
 
 
Discussion 
 
A possible explanation is that there is a high 
activity of type 2 immune response in patients with an 
exogenous form of AD with CC genotype. Probiotics 
are likely to cause the most active suppression of 
inflammation precisely in such a cohort of patients. 
A randomised double-blinded placebo-
controlled pilot study showed significantly improved 
oxidative stress values during probiotics treatment in 
inflammatory bowel disease [18]. In another clinical 
trial, it was shown that probiotics supplementation 
reduced the incidence of infections in the oral cavity 
and respiratory tracts without any drugs-related 
adverse effects [19]. 
It has been investigated that the positive 
effect of probiotics comes from several possible 
immunological mechanisms, including the modulation 
of Tx cell activation, the induction of regulatory T-
lymphocytes (Treg), and improved restoration of the 
barrier function [20]. Probiotic bacterial strains have 
been shown to inhibit Tx-2 cell responses and 
stimulate the production of cytokines by T-helper type 
1 [21]. Also, the use of probiotics increases the 
number of populations of T-regulatory lymphocytes in 
experimental models of allergic diseases, including 
AD [22], [23], most likely inducing regulatory dendritic 
cells [24]. 
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In a randomised, double-blind, placebo-
controlled study, clinical efficacy in the administration 
of probiotic strains (Lactobacillus salivarills LS01) in 
the treatment of adult AD patients was evaluated. 
There were included 38 AD patients who took 
probiotics for 16 weeks. Patients receiving probiotics 
showed a statistically lower SCORAD (p < 0.0001) 
and DLQI (p = 0.021) indices at the end of treatment 
compared to the placebo group. It has also been 
shown that the treatment of L.salivarius LSO1 reduces 
the production of cytokines Th2 type while maintaining 
a stable concentration of Th1 cytokines. At the end of 
treatment, there was also a statistically significant 
decrease in staphylococci in faeces in patients taking 
probiotics [25]. 
In this pilot study we found that the addition of 
probiotics (Lactobacillus acidophilus, LA-5 and 
Bifidobacterium animalis subsp. lactis, ВВ-12) to 
standard treatment protocol of AD (ointment of 
fluticasone propionate 0.005%, emollient) significantly 
increased the effectiveness of treatment of atopic 
dermatitis in adults with exogenous form and CC 
genotype (C-159T). Favourable outcome was 
confirmed by clinical (a significant decrease of 
SCORAD and DLQI indices) and immunological 
criteria (a significant decrease of IL-4 and an increase 
of TGF-β).  
Interpretation of the results of this study is 
based on data of a small number of patients, which 
requires further study of this problem with the 
involvement of more patients. 
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